Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
ChiCTR2000035052Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival (PFS) by mRECIST. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000035052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035052.